The Year in Nicotine: 2013 in Review

2013 was a different world for nicotine. E-cigarettes existed but hadn't yet become the JUUL-powered youth epidemic that would define the late 2010s. The disposables that now dominate global youth markets—Elf Bar, Lost Mary—hadn't been invented. Nicotine pouches were a Swedish curiosity, not a global phenomenon. Heated tobacco was a niche product in early Japanese and Italian test markets. The debate that would consume the public health community for the next decade—harm reduction or precaution, vaping as cessation tool or youth threat—was in its infancy. Looking back at 2013 from the vantage point of 2026, the year appears as a hinge: the moment when the ingredients of the modern nicotine landscape were assembled but not yet combined. The story of the decade that followed is the story of how those ingredients interacted—and how the public health community struggled to respond.

The most significant nicotine event of 2013 was not a product launch or a policy change but a regulatory announcement. In April, the FDA announced its intention to 'deem' e-cigarettes to be tobacco products subject to its regulatory authority—a decision that would take years to finalize but that signaled, for the first time, that the U.S. government intended to regulate vaping. The announcement triggered a political battle that's still ongoing: what regulatory framework should apply to non-combustible nicotine products? Are they tobacco products (subject to the Tobacco Control Act), pharmaceuticals (subject to FDA drug approval), or consumer products (subject to general product safety regulations)? The question has not been resolved. The FDA is still litigating it, and the global regulatory landscape that has emerged—a patchwork of different frameworks in different countries—reflects the unresolved tension at the heart of the 2013 announcement.

The product that would ultimately define the decade—JUUL—was founded in 2015, but its technological foundation was laid earlier. The development of nicotine salt e-liquids, which use benzoic acid to smooth the throat hit of high-concentration nicotine and dramatically increase the speed and efficiency of nicotine delivery, was a 2013-era innovation that didn't reach the mass market until JUUL launched. The nicotine salt technology was genuinely innovative—it solved a real problem (freebase nicotine e-liquids couldn't deliver cigarette-like nicotine pharmacokinetics without an intolerable throat hit) and created a product that was more satisfying for smokers and more addictive for never-smokers. The technology itself was neutral. Its population health effects depended on who used it and how it was marketed—and the marketing, when it came, was disastrous for public health.

The international tobacco control framework was at a different stage of development in 2013. The FCTC had been in force for eight years and had achieved near-universal ratification, but its implementation was (and remains) incomplete. The Illicit Trade Protocol had been adopted but not yet entered into force. The debate over novel nicotine products had not yet reached the COP. MPOWER was the dominant framework, and it was built for a world of combustible cigarettes—a world that was already beginning to change. The seeds of the tension that now structures the global nicotine debate—between the FCTC's precautionary, abstinence-oriented framework and the emerging evidence of harm reduction—were present in 2013 but not yet visible. They would germinate over the following decade.

The public understanding of nicotine in 2013 was dominated by the 'nicotine is poison' narrative that had been central to anti-smoking messaging for decades. The distinction between nicotine (addictive, not benign, but not the primary cause of smoking-related disease) and tobacco smoke (the delivery system that causes the vast majority of harm) was understood by researchers but had not penetrated public consciousness. The idea that nicotine itself, separated from smoke, might be a manageable public health outcome—the harm-reduction framework—was marginal. The communications environment was simpler than it is today: smoking kills, nicotine is addictive, quit entirely. The complexity of the modern landscape—where nicotine products exist on a risk continuum, where the optimal policy depends on who's using what, where the same product can be beneficial for one population and harmful for another—was not yet part of the public conversation.

The research infrastructure for evaluating the long-term health effects of non-combustible nicotine products was minimal in 2013. The first long-term cohort studies of vapers wouldn't begin reporting for years, and the biomarker studies that now provide the bulk of the evidence for reduced toxicant exposure were just getting underway. The precautionary principle—'we don't know the long-term effects, so be careful'—was a reasonable position given the available evidence in 2013. The question, a decade later, is whether it's still reasonable, or whether the accumulation of reassuring biomarker data, the absence of an emerging disease signal in long-term vapers, and the continuing toll of smoking-related mortality have shifted the precautionary calculus. The evidence has advanced dramatically since 2013. The policy framework has not advanced commensurately.

Looking back at 2013 is a reminder of how much has changed—and how much hasn't. The products have been transformed. The regulatory frameworks have been stretched to their limits. The evidence base has expanded enormously. But the fundamental questions remain the same: How do we minimize the total harm from nicotine? What role should non-combustible products play in that effort? How do we protect youth while supporting adult smokers? The answers available in 2013 were tentative and incomplete. The answers available in 2026 are more robust but still incomplete—and still contested. The year 2013 was the beginning of a transformation that is still unfolding. The decade that followed was turbulent, tragic, and occasionally hopeful. The decade to come will determine whether the transformation succeeds or fails.